Most Commonly Prescribed LABAs and ICS Dosing for Asthma Steps 2 and 3
For Step 3 asthma management, the most commonly prescribed LABAs are salmeterol and formoterol, typically combined with inhaled corticosteroids; Step 2 initiates with low-dose ICS (e.g., fluticasone 100-250 mcg/day or equivalent), and Step 3 escalates to either low-dose ICS plus LABA or medium-dose ICS alone (fluticasone >250-500 mcg/day or equivalent). 1, 2
Step 2: Initial ICS Dosing
Low-dose ICS is the preferred treatment at Step 2:
- Fluticasone propionate: 100-250 mcg/day
- Budesonide: Equivalent dosing to fluticasone
- Beclomethasone: Equivalent dosing to fluticasone
These represent the doses at which approximately 80-90% of maximum therapeutic benefit is achieved 1. The guidelines specifically mention fluticasone (Flovent) as a commonly used option 1.
Step 3: LABA Options and Increased ICS Dosing
Preferred LABAs for Step 3:
Salmeterol
- Typically combined with fluticasone as fluticasone/salmeterol (Advair)
- This is the most frequently cited combination in the guidelines 1, 2
- Dosed twice daily
Formoterol
- Typically combined with budesonide as budesonide/formoterol (Symbicort)
- Has rapid onset of action, making it suitable for both maintenance and reliever therapy (SMART regimen) 2, 3
- Dosed twice daily for maintenance
ICS Dose Escalation at Step 3:
The guidelines provide two preferred options 1:
- Low-dose ICS plus LABA (maintaining fluticasone 100-250 mcg/day or equivalent with added LABA)
- Medium-dose ICS alone (fluticasone >250-500 mcg/day or equivalent)
Practical Prescribing Examples
Step 2 → Step 3 progression:
- Starting at Step 2: Fluticasone 100-250 mcg/day (e.g., 100 mcg twice daily)
- Advancing to Step 3 (Option 1): Fluticasone/salmeterol 100/50 mcg twice daily (maintaining low-dose ICS, adding LABA)
- Advancing to Step 3 (Option 2): Fluticasone 250 mcg twice daily (medium-dose ICS alone)
Alternative Step 3 combination:
- Budesonide/formoterol 160/4.5 mcg twice daily (low-dose ICS/LABA combination)
Important Clinical Considerations
LABA is the preferred adjunctive therapy to combine with ICS in patients 12 years and older at Step 3, superior to leukotriene receptor antagonists or theophylline 2. The combination of ICS/LABA provides better lung function outcomes than ICS alone 1.
Never prescribe LABA as monotherapy for asthma—it must always be combined with ICS 2. This is a critical safety consideration.
Formoterol's unique advantage: Its rapid onset allows for use in maintenance and reliever therapy (SMART) regimens at Steps 3-4, where patients use budesonide/formoterol both as scheduled maintenance and as-needed for symptom relief 3, 4. This approach is currently off-label in many settings but supported by evidence 3.
Common pitfall: The guidelines emphasize that before stepping up from Step 2 to Step 3, verify inhaler technique, medication adherence, and environmental trigger control 1, 4. Many apparent treatment failures are actually adherence or technique issues rather than inadequate dosing.